1261394-64-2
1261394-64-2
Chemical Structure
Lamivudine-13C,15N3
Synonym(s): BCH-189-13C,15N3
- CAS No.: 1261394-64-2
- Formula:C713CH1115N3O3S
- Molecular Weight:233.23
InChIKey: JTEGQNOMFQHVDC-GKMPVLPASA-N
SMILES: O=[13C]1[15N](C=CC([15NH2])=[15N]1)[C@H]2O[C@H](SC2)CO
Biological Activity: Lamivudine-13C,15N3 (BCH-189-13C,15N3) is 13C and 15N labeled Lamivudine. Lamivudine (BCH-189) is an orally active nucleoside reverse transcriptase inhibitor (NRTI). Lamivudine can inhibit HIV reverse transcriptase 1/2 and also the reverse transcriptase of hepatitis B virus. Lamivudine salicylate can penetrate the CNS[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Lamivudine-13C,15N3 | Lamivudine-13C,15N3 (BCH-189-13C,15N3) is 13C and 15N labeled Lamivudine. Lamivudine (BCH-189) is an orally active nucleoside reverse transcriptase inhibitor (NRTI). Lamivudine can inhibit HIV reverse transcriptase 1/2 and also the reverse transcriptase of hepatitis B virus. Lamivudine salicylate can penetrate the CNS. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Lamivudine (Standard) | 99.85% | Lamivudine (Standard) is the analytical standard of Lamivudine. This product is intended for research and analytical applications. Lamivudine (BCH-189) is an orally active nucleoside reverse transcriptase inhibitor (NRTI). Lamivudine can inhibit HIV reverse transcriptase 1/2 and also the reverse transcriptase of hepatitis B virus. Lamivudine salicylate can penetrate the CNS. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Lamivudine-15N2,13C | Lamivudine-15N2,13C (BCH-189-15N2,13C) is 13C and 15N labeled Lamivudine. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Lamivudine-13C,15N2,d2 | Lamivudine-13C,15N2,d2 (BCH-189-13C,15N2,d2) is a 13C, 15N, and deuterium labeled Lamivudine (HY-B0250). Lamivudine is an orally active and blood-brain barrier permeable nucleoside reverse transcriptase inhibitor (NRTI). Lamivudine inhibits HIV reverse transcriptase 1 and 2 and hepatitis B virus (HBV) reverse transcriptase. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Lamivudine-15N,d2 | Lamivudine-15N,d2 is 15N and deuterated labeled Lamivudine (HY-B0250). Lamivudine (BCH-189) is an orally active nucleoside reverse transcriptase inhibitor (NRTI). Lamivudine can inhibit HIV reverse transcriptase 1/2 and also the reverse transcriptase of hepatitis B virus. Lamivudine salicylate can penetrate the CNS. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Lamivudine | 99.97% | Lamivudine (BCH-189) is an orally active nucleoside reverse transcriptase inhibitor (NRTI). Lamivudine can inhibit HIV reverse transcriptase 1/2 and also the reverse transcriptase of hepatitis B virus. Lamivudine salicylate can penetrate the CNS. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
- [2]. Colledge D, et al. Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro. Hepatology. 1997 Jul;26(1):216-25. [Content Brief]
